Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.
Belvisi D, Canevelli M, Baione V, Buscarinu MC, Pellicciari G, Fantozzi R, Creta A, Cecchi G, Cola G, Nicoletti CG, Cortese A, De Giglio L, Tartaglia M, Crisafulli SG, Bruno G, Ferraro E, Marfia GA, Centonze D, Salvetti M, Conte A. Belvisi D, et al. Among authors: marfia ga. Mult Scler. 2021 Oct;27(12):1939-1947. doi: 10.1177/1352458520987541. Epub 2021 Feb 10. Mult Scler. 2021. PMID: 33565913
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group. Landi D, et al. Among authors: marfia ga. Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740. Epub 2017 Feb 22. Neurology. 2017. PMID: 28228569 Free article.
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue.".
Landi D, Centonze D, Marfia GA, Capra R, Scarpazza C. Landi D, et al. Among authors: marfia ga. J Clin Apher. 2018 Jun;33(3):450-451. doi: 10.1002/jca.21616. Epub 2018 Feb 12. J Clin Apher. 2018. PMID: 29430694 No abstract available.
Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
Signoriello E, Landi D, Monteleone F, Saccà F, Nicoletti CG, Buttari F, Sica F, Marfia GA, Di Iorio G, Lus G, Centonze D. Signoriello E, et al. Among authors: marfia ga. Mult Scler Relat Disord. 2018 Feb;20:215-219. doi: 10.1016/j.msard.2018.02.002. Epub 2018 Feb 5. Mult Scler Relat Disord. 2018. PMID: 29433094
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M. Prosperini L, et al. Among authors: marfia ga. Neurology. 2018 Jul 10;91(2):e153-e161. doi: 10.1212/WNL.0000000000005772. Epub 2018 Jun 6. Neurology. 2018. PMID: 29875218 Clinical Trial.
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study).
Patti F, Chisari CG, D'Amico E, Annovazzi P, Banfi P, Bergamaschi R, Clerici R, Conti MZ, Cortese A, Fantozzi R, Fischetti M, Frigo M, Gatto M, Immovilli P, Leoni S, Malucchi S, Maniscalco G, Marfia GA, Paolicelli D, Perini P, Serrati C, Sola P, Totaro R, Turano G, Valentino P, Zaffaroni M, Zuliani C, Centonze D. Patti F, et al. Among authors: marfia ga. Mult Scler Relat Disord. 2020 Jul;42:102124. doi: 10.1016/j.msard.2020.102124. Epub 2020 Apr 13. Mult Scler Relat Disord. 2020. PMID: 32353755 Free article.
194 results